Selecta Stock Analysis

SELB -  USA Stock  

USD 3.73  0.28  8.12%

The current bullish price patterns experienced by current Selecta Biosciences shareholders created some momentum for investors as it was traded today as low as 3.44 and as high as 3.74 per share. The company directors and management have been very successful in rebalancing the company assets at opportune times to take advantage of market volatility in June. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.16. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Selecta Biosciences partners.
Additionally, take a look at World Market Map.

Search Stock Analysis 

 
Refresh
The Selecta Biosciences stock analysis report makes it easy to digest most publicly released information about Selecta Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Selecta Stock analysis module also helps to analyze the Selecta Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Selecta Stock Analysis Notes

About 29.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.7. Selecta Biosciences had not issued any dividends in recent years. Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts. Selecta Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 43 people. To find out more about Selecta Biosciences contact Carsten Brunn at 617 923-1400 or learn more at www.selectabio.com.

Selecta Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Selecta Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Selecta Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Selecta Biosciences has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 27.65 M. Net Loss for the year was (73.85 M) with loss before overhead, payroll, taxes, and interest of (37.91 M).
Selecta Biosciences has a frail financial position based on the latest SEC disclosures
About 29.0% of the company outstanding shares are owned by corporate insiders
Latest headline from www.globenewswire.com: Selecta Biosciences Announces Appointment of Jude Samulski, Ph.D. as Gene Therapy Special Advisor and the - GlobeNewswire

Selecta Biosciences Upcoming and Recent Events

Earnings reports are used by Selecta Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Selecta Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Selecta Largest EPS Surprises

Earnings surprises can significantly impact Selecta Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-03-11
2020-12-31-0.1243-0.14-0.015712 
2020-08-06
2020-06-30-0.206-0.25-0.04421 
2019-05-09
2019-03-31-0.354-0.310.04412 
View All Earnings Estimates

Selecta Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 383.73 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Selecta Biosciences's market, we take the total number of its shares issued and multiply it by Selecta Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Selecta Profitablity

Selecta Biosciences' profitability indicators refer to fundamental financial ratios that showcase Selecta Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Selecta Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Selecta Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Selecta Biosciences' profitability requires more research than a typical breakdown of Selecta Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (267.13) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (163.33) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.63.
Last ReportedProjected for 2021
Return on Investment(333.37) (359.69) 
Return on Average Assets(51.98) (56.08) 
Return on Average Equity-4.3 K-4.4 K

Management Efficiency

The entity has return on total asset (ROA) of (21.26) % which means that it has lost $21.26 on every $100 spent on asset. This is way below average. Selecta Biosciences management efficiency ratios could be used to measure how well selecta biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of July 28, 2021, Return on Investment is expected to decline to -359.69. In addition to that, Return on Average Assets is expected to decline to -56.08. Selecta Biosciences Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 165.44 Million. The current year Current Assets is expected to grow to about 163.3 M, whereas Revenue to Assets are forecasted to decline to 0.1.

Technical Drivers

As of the 28th of July, Selecta Biosciences has the coefficient of variation of (9,756), and Risk Adjusted Performance of 9.0E-4. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Selecta Biosciences, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Selecta Biosciences, which can be compared to its competition. Please validate Selecta Biosciences value at risk, and the relationship between the jensen alpha and semi variance to decide if Selecta Biosciences is priced more or less accurately, providing market reflects its prevalent price of 3.73 per share. Given that Selecta Biosciences has jensen alpha of (0.07), we advise you to double-check Selecta Biosciences's current market performance to make sure the company can sustain itself at a future point.

Selecta Biosciences Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of Selecta Biosciences's momentum and the point in time when Selecta Biosciences has higher than normal probability directional change. View also all equity analysis or get more info about parabolic sar overlap studies indicator.

Selecta Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Selecta Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Selecta Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Selecta Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Desilva Nishan M over two weeks ago via Macroaxis 
Acquisition by Desilva Nishan M of 80000 shares of Selecta Biosciences subject to Rule 16b-3
Donohue Ann K over a month ago via Macroaxis 
Selecta Biosciences exotic insider transaction detected
Traber Peter G over two months ago via Macroaxis 
Purchase by Traber Peter G of 20000 shares of Selecta Biosciences
Traber Peter G over two months ago via Macroaxis 
Purchase by Traber Peter G of 5000 shares of Selecta Biosciences
Timothy Springer over two months ago via Macroaxis 
Selecta Biosciences exotic insider transaction detected
Takashi Kishimoto over two months ago via Macroaxis 
Exercise or conversion by Takashi Kishimoto of 13629 shares of Selecta Biosciences subject to Rule 16b-3
Aymeric Sallin over three months ago via Macroaxis 
Acquisition by Aymeric Sallin of 40000 shares of Selecta Biosciences subject to Rule 16b-3
Timothy Barabe over three months ago via Macroaxis 
Purchase by Timothy Barabe of 10000 shares of Selecta Biosciences
Lloyd Johnston over three months ago via Macroaxis 
Sale by Lloyd Johnston of 15128 shares of Selecta Biosciences
Carsten Brunn over three months ago via Macroaxis 
Exercise or conversion by Carsten Brunn of 10937 shares of Selecta Biosciences subject to Rule 16b-3
Lloyd Johnston over three months ago via Macroaxis 
Exercise or conversion by Lloyd Johnston of 44871 shares of Selecta Biosciences subject to Rule 16b-3
Dahms Bradford D over six months ago via Macroaxis 
Acquisition by Dahms Bradford D of 230000 shares of Selecta Biosciences subject to Rule 16b-3

Selecta Biosciences Predictive Daily Indicators

Selecta Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Selecta Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Selecta Biosciences Forecast Models

Selecta Biosciences time-series forecasting models is one of many Selecta Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Selecta Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Selecta Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Selecta Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Selecta shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Selecta Biosciences. By using and applying Selecta Stock analysis, traders can create a robust methodology for identifying Selecta entry and exit points for their positions.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts. Selecta Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 43 people.

Current Selecta Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Selecta analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Selecta analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.2Buy5Odds
Selecta Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Selecta analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Selecta stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Selecta Biosciences, talking to its executives and customers, or listening to Selecta conference calls.
Selecta Analyst Advice Details

Selecta Stock Analysis Indicators

Selecta Biosciences stock analysis indicators help investors evaluate how Selecta Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Selecta Biosciences shares will generate the highest return on investment. By understating and applying Selecta Biosciences stock analysis, traders can identify Selecta Biosciences position entry and exit signals to maximize returns.
Quick Ratio1.85
Fifty Two Week Low1.4700
Shares Short Prior Month7.7M
Average Daily Volume Last 10 Day990.15k
Average Daily Volume In Three Month1.24M
Shares Percent Shares Out6.87%
Gross Margins-90.93%
Short Percent Of Float11.66%
Forward Price Earnings-7.53
Float Shares80.3M
Fifty Two Week High5.7000
Enterprise Value To Ebitda-9.06
Fifty Day Average4.2938
Two Hundred Day Average4.0495
Enterprise Value To Revenue14.56
Additionally, take a look at World Market Map. Note that the Selecta Biosciences information on this page should be used as a complementary analysis to other Selecta Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Selecta Stock analysis

When running Selecta Biosciences price analysis, check to measure Selecta Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Selecta Biosciences is operating at the current time. Most of Selecta Biosciences' value examination focuses on studying past and present price action to predict the probability of Selecta Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Selecta Biosciences' price. Additionally, you may evaluate how the addition of Selecta Biosciences to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
The market value of Selecta Biosciences is measured differently than its book value, which is the value of Selecta that is recorded on the company's balance sheet. Investors also form their own opinion of Selecta Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Selecta Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Selecta Biosciences' market value can be influenced by many factors that don't directly affect Selecta Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Selecta Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Selecta Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Selecta Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.